Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Design, synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[a]quinolizines with non-aromatic substituents in the S1 specificity pocket. One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented.

[1]  K. Ninomiya,et al.  Phosphorus in organic synthesis—VII , 1974 .

[2]  P. Van der Veken,et al.  Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. , 2007, Current topics in medicinal chemistry.

[3]  K. Mori,et al.  Synthesis of optically active forms of a-factor the inducer of streptomycin biosynthesis in inactive mutants of streptomyces griseus☆ , 1982 .

[4]  Gary M. Coppola,et al.  Chapter 19. DPP-IV inhibition and therapeutic potential , 2001 .

[5]  M. Kirby,et al.  Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. , 2009, Clinical science.

[6]  H. Lindlar,et al.  Syntheseversuche in der Emetin‐Reihe. 1. Mitteilung. 2‐Oxo‐hydrobenzo[a]chinolizine , 1958 .

[7]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[8]  B. Ahrén.  Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes , 2008 .

[9]  John Fawcett,et al.  Asymmetric synthesis of A-factor , 1998 .

[10]  G. Gribble.  Sodium borohydride in carboxylic acid media: a phenomenal reduction system , 1999 .

[11]  S. L. Gwaltney.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. , 2008, Current topics in medicinal chemistry.

[12]  G. Pez,et al.  BIS(2-METHOXYETHYL)AMINOSULFUR TRIFLUORIDE : A NEW BROAD-SPECTRUM DEOXOFLUORINATING AGENT WITH ENHANCED THERMAL STABILITY , 1999 .

[13]  Jens-Uwe Peters,et al.  1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[14]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[15]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[16]  Silja Weber,et al.  Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.

[17]  Z. Pei.  From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. , 2008, Current opinion in drug discovery & development.

[18]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[19]  R. Lüllmann-Rauch,et al.  The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. , 1996, Toxicology.

[20]  R. Pederson,et al.  Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. , 2002, Diabetes.

[21]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[22]  Jörg Huwyler,et al.  In silico prediction of brain and CSF permeation of small molecules using PLS regression models. , 2008, European journal of medicinal chemistry.

[23]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.